Consult Dr Sainath Bhethanabhotla Online Oncology

Profile Description

Dr. Sainath Bhethanabhotla – Oncologist in Gachibowli, Hyderabad

Dr. Sainath Bhethanabhotla is a leading Oncologist in Gachibowli, Hyderabad, serving as Senior Consultant & Head – Medical Oncology & Bone Marrow Transplant, with over 18 years of experience in cancer care. Patients searching for “best oncologist in Gachibowli Hyderabad,” “cancer specialist near me,” “bone marrow transplant doctor in Hyderabad,” or “pediatric oncologist in Hyderabad” trust Dr. Sainath for advanced, evidence-based, and compassionate cancer treatment.

He holds MBBS from Osmania Medical College, MD Pediatrics (Gold Medalist) from AIIMS New Delhi, and DM Medical Oncology from AIIMS New Delhi. His expertise spans adult and pediatric oncology, with a special focus on Hodgkin lymphoma, blood cancers, and bone marrow transplantation.

As a highly regarded oncologist in Hyderabad, Dr. Sainath combines precision oncology, immunotherapy, targeted therapy, and genomic-based personalized treatment to achieve the best outcomes for his patients.

Experience

Dr. Sainath Bhethanabhotla brings 18+ years of extensive clinical experience in oncology, pediatric hemato-oncology, and bone marrow transplant.

His professional experience includes:

Senior Consultant & Head – Medical Oncology & Bone Marrow Transplant
Experience at leading institutions:
MNJ Institute of Oncology & Regional Cancer Centre
Krishna Institute of Medical Sciences (KIMS), Hyderabad
CARE Hospitals, Hyderabad
Soumya Hospitals, Hyderabad
Key Clinical Expertise:
Treatment of solid tumors and hematological malignancies
Advanced bone marrow transplant (BMT) and cellular therapies
Management of pediatric cancers and neonatal oncology cases
Precision oncology using genomic testing and personalized treatment
Expertise in chemotherapy, immunotherapy, and targeted therapy
Multidisciplinary cancer care and long-term survivorship planning

Patients from Gachibowli, Hitech City, Kondapur, Madhapur, and across Hyderabad frequently search for a top oncologist in Gachibowli, and rely on Dr. Sainath for comprehensive cancer care.

Qualifications

MBBS, MD Pediatrics, DM Medical Oncology

Research & Publications

• 19 publications in highly reputed international journals with total 135 citations
• Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Post-treatment PET-CT Rather than Interim PET-CT Using Deauville criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: a Prospective Study Comparing PET-CT versus Conventional Imaging. J Nucl Med. 2016 Oct 6; (IMPACT FACTOR – 10.06)
• Bhethanabhotla S, Bakhshi S. Presence of risk factors does not affect outcome in early-stage pediatric Hodgkin lymphoma treated with ABVD. Ann Hematol. 2016 Nov 18; (IMPACT FACTOR – 3.63)
• Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2016 Dec 6;1–7. (IMPACT FACTOR – 2.99)
• Bhethanabhotla S, Bakhshi S. Reply: Neither post-treatment PET-CT nor interim PET-CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma. J Nucl Med. 2016 Dec 8; (IMPACT FACTOR – 10.06)
• Bhethanabhotla S, Tiwari A, Sharma MC, Vishnubhatla S, Bakhshi S. Prognostic Significance of IL-6 in Hodgkin Lymphoma. Indian J Pediatr. 2019 June 1;86(6):551–4. (IMPACT FACTOR – 1.96)
• Mittal A, Bhethanabhotla S, Ganguly S, Vishnubhatla S, Khadgawat R, Patel C, et al. Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy. Pediatr Blood Cancer. 2021 Nov;68(11):e29293. (IMPACT FACTOR – 3.16)
• Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal Cancer Chemotherapy during COVID-19 Pandemic. Indian J Med Paediatr Oncol. 2020 Mar;41(2):156–60.
• Bhethanabhotla S, Thukral A, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Effect of position of infant during phototherapy in management of hyperbilirubinemia in late preterm and term neonates: a randomized controlled trial. J Perinatol. 2013 Oct;33(10):795–9. (IMPACT FACTOR – 2.52)